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Abstract
Purpose of Review Hypertension is a common disorder with
substantial impactonpublichealthdue tohighlyelevatedcardio-
vascular risk. The mechanisms still remain unclear and treat-
ments are not sufficient to reduce risk in majority of patients.
Inflammatory mechanisms may provide an important mecha-
nism linking hypertension and cardiovascular risk. We aim to
reviewnewly identified immune and inflammatorymechanisms
of hypertension with focus on their potential therapeutic impact.
Recent Findings In addition to the established role of the vas-
culature, kidneys andcentral nervous systeminpathogenesisof
hypertension, low-grade inflammation contributes to this dis-
order as indicated by experimental models and GWAS studies
pointing to SH2B3 immune gene as top key driver of hyperten-
sion. Immune responses in hypertension are greatly driven by
neoantigens generated by oxidative stress and modulated by
chemokines such as RANTES, IP-10 and microRNAs includ-
ing miR-21 and miR-155 with other molecules under investi-
gation. Cells of both innate and adoptive immune system infil-
trate vasculature andkidneys, affecting their functionby releas-
ing pro-inflammatory mediators and reactive oxygen species.
Summary Immune and inflammatory mechanisms of hyper-
tension provide a link between high blood pressure and in-
creased cardiovascular risk, and reduction of blood pressure
without attention to these underlying mechanisms is not suf-
ficient to reduce risk.
Keywords Hypertension . Immune system . Inflammation .
Cytokines . Tcells . Vascular function . microRNA
Introduction
Hypertension (HT) isacommondisorderwithsubstantial impact
on public health because of its potential sequelae of stroke, heart
failure and kidney disease; subsequently, it is a major source of
morbidity and mortality [1]. It affects 30% of adults in Europe
andUSAwith additional 30% at high risk of the disease [2], and
importantly, its prevalence increases with age [3].
Despite the progress in its diagnosis and treatment, the
aetiology of HT remains unclear and a matter of substantial de-
bate. It is widely acknowledged that function of the vascular
system, kidneys and sympathetic nervous system is critical for
control and maintenance of blood pressure (BP) [1]. Vascular
resistance, stiffnessand remodellingaswell endothelialdysfunc-
tion are hallmarks of HT [4–7]. Kidney transplantation from
hypertensive donors rises BP in recipients in animal and human
studies [8,9].Sympatheticnervoussystemhyperactivitycontrib-
utes to initiation, maintenance and progression of HT [10].
Furthermore, deletion of extracellular superoxide dismutase or
administration of angiotensin II (Ang II) into circumventricular
organs (CVO) raises blood pressure, while lesions of these re-
gions prevent experimental HT [11, 12].
Inflammation—Hallmark of Hypertension
In addition to established roles of the vasculature, kidneys and
central nervous system, there is a mounting evidence, to
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suggest that chronic low-grade inflammation contributes to
cardiovascular disease (CVD) [13••, 14], including HT [15].
For instance, C-reactive protein (CRP) is a prototypic marker
of inflammation which is elevated in many CVD such as acute
myocardial infraction, coronary artery disease and HT [13••,
16]. Vongpatanasin et al. have shown that modest elevations
in CRP are sufficient not only to increase BP but also exag-
gerate response to Ang II [17]. Furthermore, human and ani-
mal studies emphasize impact of CRP on endothelial vasodi-
lator function [18, 19] via direct action on endothelial nitric
oxide synthase (eNOS) and/or activation of vascular NADPH
oxidases leading to reactive oxygen species (ROS) formation
[19–21]. In addition to CRP, the inflammatory process in-
volves a complex interplay between cells and pro-
inflammatory cytokines. This process is strictly controlled
by the immune system. Various cells of the innate and adap-
tive immune systems contribute to initiation and maintenance
of inflammation. Furthermore, resolution of inflammation oc-
curs by different mechanism in many CVD, including HT.
Link Between Immune Cells and Hypertension
The concept that the immune system contributes to hyperten-
sion is not new. Fifty years ago, the pioneering study of White
and Grollman described the role of immunosuppressive ther-
apy on BP levels in rats with kidney infarction [22]. Further
studies have shown that the transfer of immune cells isolated
from lymph nodes or spleen of hypertensive animals increases
BP in normotensive recipients [23, 24]. Moreover, thymecto-
my of deoxycorticosterone acate (DOCA)-salt-treated mice
[25] or spontaneously hypertensive rats [26] attenuates exper-
imental HT. Despite the above-mentioned studies showing the
potential role of the immune system in HT, lack of advanced
animal models and methodology did not allow for a more
thorough understanding this phenomenon.
T Cells
In 2007, the landmark study by Guzik et al. demonstrated that
HT induced by Ang II or DOCA salt is blunted in RAG1−/−
mice lacking functional lymphocytes, and the hypertensive
response is restored by adoptive transfer of T but not B lym-
phocytes [27]. These results were subsequently confirmed by
Crowley et al., who showed that T cells are essential for the
full development of AngII-dependent HT in immunodeficient
scid mice [28] and by Mattson et al., who demonstrated a
similar phenomenon in RAG1−/− rats [29]. In addition to this,
mycophenolate immunosuppressive therapy which, inhibits T
cell proliferation, reduces BP in Dahl salt-sensitive rats [30]. It
is known that Ang II acts through the AT1 and AT2 receptors,
both of which are present on the surface of T cells [26].
Furthermore, adoptive transfer of AT1 receptor deficient T
cells into RAG1−/− animals leads to a blunted hypertensive
response in Ang II-induced hypertension [27]. Infusion of
Ang II increases the percentage of circulating T cells with
effector phenotype (CD69+, CD25+, CCR5+) in both
in vivo and in vitro studies [27, 31]. Additionally, T cells with
effector phenotype accumulate in perivascular adipose tissue
(PVAT) and kidneys, and affect endothelial function and vas-
cular fibrosis [30–32, 33•]. Interestingly, a meta-analysis of
GWAS data pointed polymorphisms in the SH2B3 gene as
significant predictors of systolic and diastolic BP. This gene
encodes for the lymphocyte adaptor protein, lnk [34]. Keeping
with this, Saleh et al. have shown that the loss of lnk exacer-
bates Ang II-induced HT and its associated renal and vascular
dysfunction. Moreover, lnk-deficient mice have increased T
cell activation and cytokine production in comparison to wild-
type animals [35]. Higher cytokine production by
immunosenescent cytotoxic CD8+ T cells (CD28 null and
positive for CD57) as well as augmentation of their number
have been previously reported in hypertensive patients [36].
Among T cells, there is a distinct subset of regulatory cells.
They express CD4 and CD25 surface markers and a forkhead
transcription factor 3 (FOXP3).This unique subset possesses the
capacity to suppress innate andadaptive immune responses [37].
ExperimentalHTisrelatedtoadeclineinthenumberofTregcells
in in vitro and in vivo studies [38, 39].Recent studieshave shown
that adoptive transfer of Treg cells reduces blood pressure [40,
41] and ameliorates endothelial function in Ang II-treated ani-
mals [39].Further studieshave shown this is accompaniedby the
attenuation of NADPH oxidase activity, which is critical in the
development of vascular dysfunction [42, 43].
B Cells
Clinical and experimental HT is associated with raised serum
IgG, IgA or IgM antibodies produced by B cells [44].
Although, transfer of B cells did not restore HT in Ang II-
infused RAG1−/− mice [27], B cell activation does appear to
be dependent on highly specific interactions with T cells [45]
which are absent in RAG1−/− animals. Recently, Drummond’s
group has shown that Ang II infusion leads to increased pro-
duction of antibodies by activated B cells. Genetic deficiency
of B-cell-activating factor receptor, or pharmacological deple-
tion of B cells, protects against BP elevation and the end organ
sequelae of Ang II such as collagen deposition and aortic
stiffness. These effects are restored by the adoptive transfer
of B cells [46].
Monocytes and Macrophages
Monocytes and macrophages have been implicated in various
models of experimental HT [47, 48]. Ang II-induced HT is
associated with an increased number of circulating monocytes
[49, 50], and their elimination leads to decreased severity of
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HT, associated reduction of vascular ROS generation and im-
provement of vascular function [49]. Monocytes are circulat-
ing precursors of macrophages, which accumulate in the
PVAT, adventitia and kidneys during HT [4, 50, 51].
Infiltrating macrophages release pro-inflammatory mediators
and produce free radicals via NOX2 NADPH oxidase that
changes vascular homeostasis [52–54]. Macrophage colony-
stimulating factor (m-CSF) deficiency is associated with at-
tenuated Ang II-induced HT, arterial remodelling, endothelial
dysfunction, superoxide generation, NADPH oxidase activa-
tion and vascular inflammation [47]. Correspondingly, phar-
macological blockade of macrophage CCR2 receptors, using
INCB3344, prevents macrophage accumulation and reverses
DOCA salt and Ang II-induced HT [50, 51].
Toll-like receptors (TLRs) have an important role in
the activation of macrophages and monocytes [55].
They provoke cytokine and chemokine production
through activation of NF-κB (nuclear factor kappa B)
[56]. TLR4 is upregulated in Ang II-induced HT. Anti-
TLR4 antibody treatment normalises BP and reduces
inflammation and vascular changes associated with HT
through MyD88-dependent activation and JNK/NF-κB
signalling pathway [57]. Similarly, neutralization of
TLR4 reduces BP and augmented vascular contractility
in adult spontaneously hypertensive rats [58]. Finally,
upon activation, macrophages and monocytes can acti-
vate T cells via antigen presentation, expression of
costimulatory ligands and release of mediators that mod-
ulate their function and/or chemotaxis [53, 55].
Dendritic Cells
Evidence suggests that dendritic cells (DCs) play a role
in the development of HT. DCs from hypertensive ani-
mals produce an increased amount of superoxide and a
wide range of cytokines (IL-1β, IL-6, IL-23), which
affect T cell polarization into the inflammatory pheno-
type [59]. Transfer of DCs from hypertensive donor
mice into C57BL/6 mice results in the development of
severe HT in response to sub-pressor dose of Ang II
while having no effect in mice that received DCs from
control animals [59]. Hypertensive mice have demon-
strated higher levels of DCs with increased expression
of costimulatory ligands CD80 and CD86, which are the
hallmark of their activation [60]. Moreover, treatment
with the pharmacological agent CTLA4-Ig (blocking
B7-dependent costimulation) resulted in reduction of
BP in both Ang II and DOCA salt-induced HT [60].
Chronic oxidative stress, associated with HT, leads to
formation of immunogenic isoketal-protein adducts,
which accumulate in DCs and promote T cell activation.
Interestingly, increased isoketal adducts are also ob-
served in immune cells of hypertensive patients [59].
Natural Killer Cells
Studies of Taherzadeh et al. have shown that NK gene com-
plex is an important determinant to genetically determined
sensitivity to develop HTand associated vascular remodelling
in L-NAME-induced HT in mice [61]. An increased number
of NK cells are also observed in the circulation of pregnant
hypertensive rats [62]. Moreover, depletion of NK cells leads
to protection from Ang II-induced vascular dysfunction [63].
Neutrophils
There are inconsistent results from studies investigating the
role of neutrophils in HT. Pharmacological depletion of this
subpopulation of leukocytes was associated with a significant
fall in systolic BP in vivo and an attenuation in phenylephrine-
induced vasoconstriction [64]. Conversely, selective depletion
of circulating neutrophils protected against oxidative stress
but not against the development of Ang II-induced HT [65].
Similarly, restoration of neutrophils in LysMiDTR-depleted
mice with monocytes did not restore pathophysiological ac-
tion of Ang II [49].
Cytokines as Key Mediators in Hypertension
During progression of HT, immune cells accumulate in target
organs, of which kidneys and the vasculature are particularly
vulnerable [4, 33•, 66] (Figure 1). These cells produce potent
cytokines that affect vascular and renal function, which are
essential for the development of HT. In recent years, numer-
ous cytokines with a crucial role in HT have been reported.
Tumour Necrosis Factor Alpha
Tumour necrosis factor alpha (TNF-α) is produced by many
cell types including immune cells, vascular cells and adipo-
cytes [67]. Various studies have shown that HT is associated
with elevated production of TNF-α by different immune cells
and a subsequent rise is observed in the circulation [27, 62, 68,
69]. Blockade of AT1 receptors in patients with HT results in a
significant reduction of circulating levels of TNF-α. Mice
lacking TNF-α gene or mice treated with etanercept (TNF-α
antagonist) do not develop HT in response to Ang II [27, 68].
Replacement therapy with recombinant TNF-α restores action
of Ang II [68]. Stimulation of endothelial cells with TNF-α
decrease eNOS expression [70] by destabilisation of eNOS
mRNA [71], which impairs ability of ECs to produce NO.
TNF-α activates NF-κB and NADPH oxidase [70], which
play an important role in the induction of oxidative stress
and overexpression of both chemokines and adhesion mole-
cules [68].
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Interferon Gamma
Another pro-inflammatory cytokine produced by various im-
mune cells which plays a role in HT is interferon gamma
(IFN-γ) [63, 72]. Experimental HT is associated with in-
creased production of IFN-γ by activated Tcells and NK cells
[4, 35, 63]. The knock down of IFN-γ results in a blunted
increase of Ang II-induced murine BP [35]. In contrast, this
phenomenon is not observed in IFN-γ receptor-1-deficient
mice [73]. Loss of lnk exacerbates production of IFN-γ by
CD8+ lymphocytes as well as enhances impairment of
endothelial-dependent relaxation as compared to wild-type
mice [35]. Interestingly, incubation of aortic segments with
IFN-γ ex vivo promotes endothelial dysfunction that is par-
tially reversed by preincubation with PEG-SOD [4], which
ameliorates oxidative stress in vasculature [74]. IFN-γ also
has a strong impact on superoxide production via upregulation
of the expression and activity of NADPH oxidases in human
aortic smooth muscle cells [75]. It acts directly on VSMC to
induce their proliferation and apoptosis [76, 77]. Furthermore,
neutralization of IFN-γ biologic action prevents outward vas-
cular remodelling of human coronary arteries induced by al-
logenic T cells in SCID/beige mice [78]. IFN-γ affects the
RAS system as well as sodium-proton-exchanger type 3 trans-
porter in the kidneys, which leads to increased production of
angiotensinogen and modulation of sodium absorption, re-
spectively [79, 80].
Interleukin 6
Interleukin 6 (IL-6) is produced by a variety of cells, including
DCs, macrophages, monocytes, Tcells and vascular cells [81].
High levels of IL-6 correlate with increased BP and may be an
independent risk factor for HT [81, 82]. In addition to this, the
IL-6 level is reduced after treatment with Ang II-receptor
blockade [83]. The increase of IL-6 is also observed in many
models of experimental HT [84–86] strongly suggesting the
essential role of IL-6 in HT. Treatment of mice with IL-6 not
only increases vascular AT1 receptor expression but also in-
duces vasoconstriction, oxidative stress and impairs endothe-
lial function [87]. IL-6 mediates elevation of superoxide pro-
duction and endothelial impairment by affecting NO-cGMP
signalling pathway [88]. Furthermore, IL-6 has been reported
to play an important role in VSMCmigration and proliferation
leading to vascular medial hypertrophy [89, 90]. Mice lacking
IL-6 are protected against the action of Ang II and stress-
induced HT [81, 85, 91]. Moreover, IL-6 promotes polariza-
tion of CD4+ T cells to produce IL-17 [92].
Interleukin 17
Interleukin 17 (IL-17) is produced mainly by the unique sub-
population of CD4+ cells called TH17. Additionally,
production of IL-17 was reported in γ/δ cells, subsets of
CD8+ T cells, some B cells and NK cells [93]. Several reports
indicate that IL-17 contributes to CVD [94–96]. Plasma levels
of IL-17 are increased in humans and animals with HT
[97–100]. Administration of recombinant IL-17 in mice
causes a modest elevation of BP in the absence of other hy-
pertensive stimuli [98]. Furthermore, genetic deletion or phar-
macological blockade of IL-17 protects animals against Ang II
and DOCA salt-induced HT, oxidative stress and endothelial
dysfunction [97, 100]. Nguyen et al. have shown that IL-17
induces phosphorylation of Thr495 on the eNOS in Rho/Rho-
kinase-dependent manner leading to decrease in NO produc-
tion and impairment of Ach-induced relaxation in ex vivo
studies [98]. Moreover, IL-17 activates ECs as demonstrated
by elevated expression of adhesion molecules and other im-
mune cells chemoattractants [101]. Mice lacking IL-17 are
protected against perivascular inflammation [100]. Recently,
Harrison’s group has shown that T cells, and especially TH17
cells, play crucial role in enhanced collagen deposition in
adventitia and aortic stiffening in experimental HT [72]. It is
evident that Il-17 induces expression of mRNA for collagens
in p38MAP-kinase-dependent fashion leading to excessive
collagen deposition and loss of aortic compliance [72].
Finally, IL-17 can induce or synergize effect of other pro-
inflammatory cytokines [102] leading to perturbation between
pro- and anti-inflammatory factors.
Interleukin 10
In contrast to previously mentioned cytokines, interleukin 10
(IL-10) possesses anti-inflammatory properties. IL-10 not on-
ly suppresses production of TNF-α, IFN-γ and IL-6 by vari-
ous immune cells [103], but also blocks the activity of pro-
inflammatory transcription factors such as NF-κB [104]. It is
produced by Tcells, mainly Treg, DCs andmacrophages [105,
106]. The IL-10 -627C/C polymorphism, associated with in-
creased expression of IL-10, reduces an incidence of HT in
Russian Tatars [107]. Hypertensive patients treated with AT1
receptor blockers or ACE inhibitors are characterized by an
elevated serum IL-10 level [108]. Furthermore, there is much
evidence that IL-10 blunts high BP in experimental models of
HT, including preeclampsia [42, 109, 110]. Mice lacking IL-
10 exhibit enhanced HT, endothelium dysfunction and in-
creased superoxide production in response to Ang II com-
pared with wild-type animals [63]. Similarly, incubation of
the IL-10−/− vessels with Ang II reduces their relaxation and
enhances superoxide production as compared to wild-type
vessels ex vivo [111]. On the other hand, administration of
IL-10 or an antioxidant can restore Ang II-induced endothelial
dysfunction [112]. IL-10, acting on ECs, upregulates expres-
sion, activity and phosphorylation of eNOS [113] and further
inhibits activation of p38 MAP-kinase, which stimulates
12 Page 4 of 12 Curr Cardiovasc Risk Rep (2017) 11: 12
production of pro-inflammatory cytokines and regulates
NADPH oxidase activity [114, 115].
Clinical Evidence Linking Immune System
and Hypertension
As stated above, experimental HT is associated with activated
immune cells and their depletion/reduction very often results
in normalization of BP. Based on the fact that immunosup-
pressive therapy is not currently clinically justified in patients
with HT, we cannot countercheck these experimental obser-
vations directly. However, there is increasing evidence
supporting the role of an immune component in the pathogen-
esis of HT in humans.
The third National Health and Nutrition Examination
Survey (NHANES III) analysed data from 5626 participants
and revealed a higher number of circulating leukocytes in
hypertensive than in normotensive participants as well as the
correlation between their number and systolic BP [116].
Increased BP is also observed in patients after infusion of
allo-activated T cells during cancer treatment [117].
Conversely, HIV-infected patients have lower incidence of
abnormally high BP [118]. Furthermore, immunosuppressive
agents, which are not nephrotoxic, can reduce the prevalence
of clinical HT [119, 120]. Reduction of BP with combination
of telmisartan and rosuvastatin is related to a decrease of
TH17/Treg ratio and of proinflammatory cytokines in hyper-
tensive patients with carotid atherosclerosis [121]. Also, he-
reditary neutropenia, observed in Yemenites, causes small but
statistically significant decline in systolic and diastolic BP in
comparison to non-Yemenites population [64].
Increased BP in humans is associated with elevation of
many pro-inflammatory mediators produced by immune cells
such as TNF-α, IFN-γ, IL-6, IL-17 and decrease of anti-
inflammatory cytokines like IL-10 [66, 69, 81, 82, 98]. This
is also supported by the fact that polymorphisms of TNF-α
and IL-6 are associated with human HT [122, 123].
Importantly, pro-inflammatory cytokines, mentioned
above, serve not only as markers of inflammation but also
confer risk for many CVD.
Other Risk Factors Affecting Development
of Hypertension and Their Link with Immune
System
Physiological stress is a significant factor for many CVD
[124]. Moreover, sympathetic nervous system participates in
development of HT [11, 12]. Marvar et al. have demonstrated
that repeated daily stress elevates BP in mice. This was asso-
ciated with activation of the immune system i.e. increase of
circulating T cells expressing CD69 and CD44high markers.
Moreover, Ang II-infused mice exposed to chronic stress
displayed greater BP than non-stressed animals. In contrast,
repeated stress did not affect BP in T and B cells depleted
RAG1−/− mice [125].
Another risk factor for HT is obesity, which is also associ-
ated with chronic inflammation, vascular remodelling and en-
dothelial dysfunction [126, 127]. Cells of both the innate and
adoptive immune system reside in adipose tissue and partici-
pate in these pathophysiological changes [128]. Moreover,
immune cells produce cytokines that can modulate expression
of classical adipokines. Production of anti-inflammatory
adiponectin can be inhibited by pro-inflammatory mediators
such as TNF-α, IL-6 and IL-17. At the same time, pro-
inflammatory cytokines can induce production of leptin which
is critical in the development of obesity [33•].
Some studies have shown an association between air
pollution exposure and the risk of HT [129]. Exposure to
PM2.5 (particulate matter <2.5 μm) and ozone increases
blood pressure in humans [130]. Similarly, PM2.5 expo-
sure in mice induces endothelial dysfunction and mild
elevation in BP, which is associated with increased levels
of inflammatory cytokines in blood (TNF-α, IL-6). In
addition to this, there is also an increased number of
activated macrophages in adipose tissue and increased
vascular adhesion of monocytes [131]. Finally,
pollutant-induced oxidative stress may affect vascular
function [132].
Micro-RNA as Novel Immune Players
in Hypertension
Micro-RNAs (miRNAs) are implicated in the intricate
control of genes throughout the body; therefore, it is
understandable that they can be associated with immune
mechanisms of hypertension (Fig. 1). MiRNAs are 18–
22 nucleotides in length and do not code for a gene but
may affect expression of other target genes. This is
achieved through a negative regulation via binding of
its complex (the RNA-induced silencing complex) to
the 3′ untranslated region (3′ UTR) of its target messen-
ger RNA (mRNA). Sixty percent of protein coding
genes have miRNA target sites in their 3′ UTR, and a
single miRNA may impact the expression of multiple
mRNAs. MiRNAs are involved in both the cellular
and clinical manifestations of various CVD diseases
such as HT [133], coronary artery disease [134] and
cardiac hypertrophy with subsequent heart failure
[135]. Further to this, miRNAs are implicated in the
immune system in the context of chronic immune dis-
orders [136–139]. Two miRNAs are discussed, which
are considered to be pro-inflammatory in nature and
demonstrated associations with chronic inflammatory
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arthritides as well as with cardiovascular manifestations
of HT.
miR-21
Micro-RNA 21 is an extensively investigated miR in the con-
text of the cardiovascular system [140•]. MiR-21 is elevated in
peripheral blood mononuclear cells (PBMCs) of hypertensive
patients and is associated with the degree of LVH detected in
this group [141]. In coronary artery disease, McDonald et al.
demonstrated that eliminatingmiR-21 reduces in stent resteno-
sis via anti-inflammatory effects ofM2macrophages, lowering
number of CD3+ T cells and a reduction of Ly6c+cells level
[134] (which differentiate to become the pro-inflammatoryM1
phenotype). It is widely accepted that nitric oxide synthase is a
marker for M1 macrophages and subsequently M1 cells pro-
duceROS.This responsewas likelyevolved tokillpathogens in
the micro environment. That being said, it is now known that
ROS elevate BP and activate pro-fibrotic signalling pathways
as reviewed in many excellent reviews including this piece by
Montezano and Touyz [142]. It is noteworthy that iNOS is not
expressedbymacrophages inhumans;however,aclinicalstudy
has shown a relationship between elevated miR-21 and endo-
thelial dysfunction with an associated reduction in NO and
eNOS levels in hypertensive patients [143]. miR-21 can mod-
ulate Tcell responses including exerting influence on cytokine
production [144]. Not onlymiR-21 is induced by Tcell activa-
tion and enhances the T cell immune response [145] but also
miR-21has been shown to induceproliferation ofCD4+Tcells
inmurinemodelsofsystemic lupuserythematosus (SLE)and in
patients with SLE [146, 147]. Relating to the production of IL-
17 from CD4+ cells, previously mentioned in this work, this
could linkmiR-21 to the increasedcardiovascular riskobserved
in patients with lupus and other inflammatory arthritides.
Further to this, miR-21 could serve as a biomarker for CVD in
this patient group. miR-21 is a positive regulator of the expres-
sion of the transcription factor, FOXP3 [148]. As previously
mentioned, Treg cells express FOXP3 and there is an associa-
tionbetweena lowernumberofTregcells andHT[38, 39].This
conflicts with the previously understood concepts that miR-21
is associated with pathological processes seen in elevated BP
suggesting the full mechanism is not yet known, thus bringing
together the development of HT, inflammatory cell lines, the
coronary arterial disease sequelae of HTandmiR-21.
miR-155
The endothelium is the single-cell surface layer lining the
entire vascular tree, and inflammation, the response to injury,
is observed in the endothelium in HT. The endothelium is the
source of eNOS, which underpins much of the vascular se-
quelae of HT. miR-155 reduces eNOS expression [149]. Mir-
155 is regarded as a pro-inflammatory miR and is necessary
for normal B cell and T cell function. In miR-155 KO mice, it
has been shown that it is implicated in the regulation of many
genes including chemokines and cytokines [150, 151]. Further
to this, TNF-α increases miR-155 expression with subsequent
negative regulation of eNOS [133, 152]. TNF-α has also been
shown to increase miR-155 expression in macrophages and
monocytes during an inflammatory response [153] helping to
Fig. 1 Immune mechanism of hypertension
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explain this phenomenon in HT. In short, the effects of TNF-α
discussed earlier in this paper are closely mediated by miR-
155. MiR-155 has been shown to regulate the AT1 receptor in
rat cardiomyocytes [154], rat aortic adventitial-derived fibro-
blasts [155] and in human PBMCs where it was also found to
correlate with BP [151]. Interestingly, rare allele of rs5186
polymorphism, located in the AT1 receptor, blocks adhe-
sion of mir-155 to the AT1 receptor 3′ UTR [156]. This
observation may explain that rs5186 was a risk factor for
HT in several epidemiological studies, although overall,
the clinical effect of this polymorphism is unclear and
further research, taking into account different subpopula-
tions of patients with HT, are needed to verify its role in
HT [157]. MiR-155 level in aortic tissue of adult sponta-
neously hypertensive rats negatively correlates with the
blood pressure [158]. This has translated into a human
study that examined miR levels in PBMCs and demon-
strated lower circulating pro-inflammatory cytokines in-
cluding TNF-α in patients who had downregulation of
miR-155 [159]. It has been shown that the 5p strand of
miR-155 is upregulated in fibroblasts in the synovial fluid
taken from patients with rheumatoid arthritis [160], sug-
gesting that miR-155 plays an important role in a chronic
inflammatory response. In summary, miR-155 is another
miR, which provides an association between inflammatory
arthritis and HT. Moreover, miR-155 is associated with
hypertension and is implicated in a pro-inflammatory phe-
notype. It is likely that these effects may have an impact in
either HT onset or severity.
Conclusions
In summary, hypertension is associated with significant acti-
vation of immune and inflammatory systems and shares sev-
eral functional differences with other immune-mediated dis-
eases. Low-grade inflammation is prominent and further un-
derstanding of specific cytokine and chemokine milieu, simi-
larities and differences between hypertension pathogenesis
and atherosclerosis will shed a light on possible new therapeu-
tic strategies to limit vascular and renal complications of HT.
Indeed, in experimental models, immune-targeted therapies
prevent vascular and renal damage and can alleviate hyperten-
sion. Evidence in humans is now urgently needed.
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